Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | CHKA | P35790 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL4775859 | 0.93 | CHRM5 (0.55) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| Acetone SCHEMBL28700630 | 0.87 | CHRM5 (0.76) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| Acetic Acid SCHEMBL7780301 | 0.85 | CHRM5 (0.73) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL9762926 | 0.83 | CHRM5 (0.76) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL28267252 | 0.81 | CHRM5 (0.73) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL28588179 | 0.81 | CHRM5 (0.73) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28166029 | 0.81 | CHRM5 (0.73) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| Propionic Acid SCHEMBL28433613 | 0.80 | CHRM5 (0.64) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28208758 | 0.80 | CHRM5 (0.64) | CHRM5CHKAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL189 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929334-A | A kind of preparation method of morpholine diketone class natural alkaloid and its derivative | 中山大学 | 2018-12-04 | — | — | CN | claimed |
| JP-63222146-A | — | — | None | — | — | JP | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| CN-106573904-B | Method for generating beraprost and its derivative | 朗格生物技术公共公益股份有限公司 | 2019-11-08 | — | — | CN | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| CN-104918949-B | The liquid-phase synthesis process of nucleic acid | 武田药品工业株式会社 | 2017-10-10 | — | — | CN | disclosed |
| CN-106573904-A | Methods for producing beraprost and its derivatives | 朗格生物技术公共公益股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-20030144532-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | GILEAD SCIENCES, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6576776-B1 | Method of manufacture of 1,3-oxathiolane nucleosides | TRIANGLE PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6518425-B1 | A process for producing a 1,3-oxathiolane nucleoside comprising reacting a 5-halo-2-protected-oxymethyl-1,3-oxathiolane with a silylated purine or pyrimidine without the addition of a Lewis acid or an additional base to the reaction | EMORY UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| EP-1104415-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | Triangle Pharmaceuticals Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| US-6215004-B1 | CYCLIZATION OF MERCAPTOACETIC ACID WITH ACETAL IN SOLVENT; SULFIDING | EMORY UNIVERSITY | 2001-04-10 | — | — | US | disclosed |
| US-6069132-A | PYRIMIDOPHOSOHAZOLE RING SYSTEM OF GIVEN STRUCTURE, THE TRIVALENT PHOSPHORUS OF THE RING SUBSTITUTED WITH VARIOUS GROUPS; NEW CLASS OF PHOSPHORUS CONTAINING HETEROCYCLES WITH APPLICATION IN MEDICAL, AGRICULTURAL AND INDUSTRIAL USE | ARONEX PHARMACEUTICALS, INC. | 2000-05-30 | — | — | US | disclosed |
| WO-2000009494-A1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| JP-S63222146-A | CYCLOPENTANONE DERIVATIVE AND PRODUCTION THEREOF | NOGUCHI KENKYUSHO | 1988-09-16 | — | — | JP | disclosed |
| EP-0210065-A1 | 6-Alkylidene penems | BEECHAM GROUP PLC (GB) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | CHRM5 894/4885CHKA 989/4885MAPT 3691/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | CHRM5 2598/4885CHKA 3464/4885MAPT 3982/4885 |
| US-20030144532-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | NUDT1, PNP, TYMP | CHRM5 3129/4885CHKA 2815/4885MAPT 3446/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | CHRM5 2113/4885CHKA 3481/4885MAPT 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.